日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non-muscle invasive bladder cancer indicates high tolerability and local immunological activity.

首次对复发性非肌层浸润性膀胱癌患者进行膀胱内三功能抗体卡妥昔单抗治疗,结果显示其具有良好的耐受性和局部免疫活性

Ruf Peter, Bauer Hartwig W, Schoberth Alexandra, Kellermann Claudia, Lindhofer Horst

Removal of EpCAM-positive tumor cells from blood collected during major oncological surgery using the Catuvab device- a pilot study

使用 Catuvab 装置从大型肿瘤手术中采集的血液中去除 EpCAM 阳性肿瘤细胞——一项初步研究

Winter, Andreas; Zacharowski, Kai; Meybohm, Patrick; Schnitzbauer, Andreas; Ruf, Peter; Kellermann, Claudia; Lindhofer, Horst

Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition

三功能双特异性抗体联合免疫检查点抑制剂可诱导强效的CD4+ T细胞相关抗肿瘤记忆反应

Deppisch, Nina; Ruf, Peter; Eißler, Nina; Lindhofer, Horst; Mocikat, Ralph

Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model

神经节苷脂GD2特异性三功能替代抗体Surek在小鼠黑色素瘤模型中显示出治疗活性

Ruf, Peter; Schäfer, Beatrix; Eissler, Nina; Mocikat, Ralph; Hess, Juergen; Plöscher, Matthias; Wosch, Susanne; Suckstorff, Ivonne; Zehetmeier, Christine; Lindhofer, Horst